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Worsening of diabetic retinopathy (DR) is associated with the initiation of effective treatment of glycaemia in some patients with diabetes. It has been associated with risk factors such as poor blood-glucose control and hypertension, and it manifests prior to the long-term benefits of optimizing glycaemic control. The majority of evidence supports an association of large and rapid reductions in blood-glucose levels with early worsening of DR. Despite a general awareness of early worsening within the diabetes community, mechanisms to explain the phenomenon remain speculative. We provide an overview of early worsening of DR and its pathophysiology based on current data. We describe the phenomenon in various settings, including in patients receiving insulin-or non-insulin-based treatments, in those undergoing bariatric surgery, and in pregnant women. We discuss various mechanisms and theories that have been suggested to explain this paradoxical phenomenon, and we summarize the implications of these in clinical practice.
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| THE EARLY WORSENING PHENOMENON IN DIABETIC RETINOPATHY
Diabetic retinopathy (DR) is a common complication of diabetes that affects the vasculature in the eye and occurs in approximately onethird of patients with diabetes. 1, 2 It is the leading cause of vision loss in the working-age and elderly population. 3 The progression and development of DR is associated with a number of risk factors, including long duration of diabetes, poor glycaemic control and poorly controlled hypertension. 2, 3 Deterioration of DR, upon initiation of stringent diabetes treatment, is referred to as "early worsening". In this context, the term "early" refers to the establishment of good glycaemic control, and not to a short duration of diabetes. This seemingly paradoxical outcome was first described in the 1980s in patients with type 1 diabetes who were treated intensively with continuous subcutaneous insulin infusion (CSII) rather than conventional treatment, that is, short-or intermediate-acting insulin. [4] [5] [6] One early report involving 18 patients with long-term (mean, 14.6 years) poorly controlled diabetes showed that changing from a period of poor control to tight control of diabetes was detrimental for patients with existing DR. In this study, seven patients experienced worsening DR, while four patients with existing moderate-to-severe DR experienced rapid progression of retinopathy within three to 6 months of CSII. 4 The timescale over which early worsening has been reported ranges from 3 months up to 3 years after treatment initiation. [7] [8] [9] [10] [11] In the Oslo study, early worsening developed after 3 months of treatment in half of the patients treated with CSII (n = 7/15) or multiple insulin injections (n = 8/15) compared with none in the conventional treatment group. 7 Similarly, in the Kroc collaborative study, almost half of the patients receiving CSII (47%) developed early worsening by Month 8 of treatment, compared to 27% in the conventional treatment group. 8 In these trials, early worsening was defined in various ways, including by progression on the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale, a standardized scale of disease severity derived from grading of retinal fundus photographs, which characterizes DR stages (also known as the diabetic retinopathy severity scale [DRSS] ) 12 and by fluorescein angiograms. [7] [8] [9] While the existence of early worsening is not in doubt, the pathophysiology of this phenomenon is not well understood. Furthermore, the circumstances under which it appears remain to be fully elucidated. Since its discovery, early worsening has been described in patients with type 1 and type 2 diabetes, including those undergoing various diabetic therapies, those who have undergone bariatric surgery, and pregnant women. 13 Here we review the current understanding of the pathophysiology of early worsening and possible underlying mechanisms. We explore the literature related to early worsening of DR in various settings, the microvascular changes that occur, and existing theories that explain early worsening.
| METHODOLOGY ON LITERATURE SEARCH STRATEGY AND SELECTION CRITERIA
A literature search was conducted using BIOSIS Previews, Current
Contents Search, EMBASE and MEDLINE databases to identify DRrelated publications. The search terms used are shown in Table 1 .
Searches covered publication dates from 1 January 2012 to 31 December 2017. A total of 167 primary and secondary articles and 41 reviews were retrieved and assessed for suitability of inclusion.
Clinically relevant publications, as decided by the authors, were also included.
Articles were considered suitable for inclusion if they covered specific topics such as the factors impacting DR progression, the rela- 12 In severe non-proliferative DR, abnormal new blood vessels grow in response to the hypoxic environment caused by capillary occlusion, which worsens ischaemia.
In proliferative DR the main pathogenic factor is retinal hypoxia, which stimulates vascular endothelial growth factor (VEGF) production, resulting in retinal neovascularization. 3 Evidence suggests that retinal neurodegeneration is an early process that precedes microvascular complications of the eye. 14 This has been reflected in guidelines from the American Diabetes Association, in which DR is referred to as a highly specific neurovascular complication of diabetes. 15 
| THE PATHOPHYSIOLOGY OF EARLY WORSENING: MECHANISM OF ACTION
The definition of early worsening of DR varies across trials, ranging from changes in severity to specific morphological changes or clinically significant progression. The definition of "worsening" has been recorded as the appearance of cotton-wool spots/soft exudates, haemorrhages, including dot-and-blot haemorrhages, "red spots" or microaneurysms, intraretinal microvascular abnormalities (IRMAs) and capillary-free areas. 6, 9, [16] [17] [18] Cotton-wool spots are lesions caused by microvascular perfusion abnormalities and secondary axoplasmic stasis. 19 The relationship between cotton-wool spots and glycaemic change is unclear. One theory suggests that a decrease in retinal blood flow may cause cotton-wool exudates to appear. This leads to an insufficient blood supply on the downstream side of arteriosclerotic arterioles. Impaired autoregulation may also be involved. 9 In the Kroc Collaboration study, patients in the intensively treated group were characterized by increased numbers of soft exudates (cotton-wool spots) and IRMAs, compared with those in the conventionally treated group, after 8 months. However, at 2 years, the number of soft exudates and IRMAs were similar in both treatment groups. 20 In the STENO study, early worsening events were characterized by soft exudates, microaneurysms and haemorrhages at 1 year. In this study, retinal morphology had improved at 2 years. 5, 9 In the Oslo study, at 3 months only subjects in the intensively treated group had significantly more microaneurysms and haemorrhages versus baseline. 6 However, at 2 years those in the conventionally treated group had significantly more microaneurysms and haemorrhages versus baseline and versus the intensively treated group. 6 In the landmark or greater progression of DR vs baseline was higher in patients with early worsening compared to those without (Table 2) . 17 Characteristically, patients with early worsening had higher HbA1c at baseline and experienced greater reductions in HbA1c during the first 6 months of treatment compared to those without. However, despite this initial deterioration in DR, intensively treated patients had similar or more favourable outcomes compared with conventionally treated patients without early worsening. Furthermore, after 10 years, once HbA1c levels had become comparable between the two treatment groups, the risk of DR progression was still significantly lower in patients who had been treated intensively compared with conventionally treated patients, and a beneficial effect persisted for up to 18 years (Table 2 ).
28,29
The effects on DR of rapid reductions in HbA1c were further shown in a retrospective 24-month case-control study, in which individuals with diabetes and progression of retinopathy (case) were compared with individuals with diabetes and no progression of retinopathy (control). In the case group, HbA1c values decreased rapidly approximately 10 to 9 months before the progression of retinopathy, whereas, in the control group, HbA1c values did not change during the entire follow-up period. The relative risk of DR progression with a 1%, 2% or 3% decrease in HbA1c for approximately 6 months was 1.7, 2.8 and 4.7, respectively ( Table 2) . 30 The effect of intensive vs conventional glycaemic targets on longterm complications in patients with type 1 diabetes was assessed in a
Cochrane-based review. 31 This review comprised 12 trials, a total of 2230 patients and a mean follow-up across trials ranging between one and 6.5 years. Findings showed that intensive vs conventional treatment was highly effective in reducing the risk of developing microvascular diabetes complications such as DR (6.2% vs 23.2%; relative risk, 0.27; 95% CI, 0.18-0.42; P < 0.00001). Furthermore, early worsening of DR was evident after only 1 year of intensive vs conventional glucose control (34.7% vs 14.9%; relative risk, 2.32; 95% CI, 1.16-4.63; P < 0.02). 31 
| EARLY WORSENING IN TYPE 2 DIABETES
The evidence for early worsening in patients with type 2 diabetes is limited because many large randomized controlled trials, for example the ADVANCE and ACCORD trials, evaluated only the effect of intensive vs conventional therapy on DR progression, assessed as retinal change at trial end rather than as an early outcome. 10, 24, 25, 32 In the UKPDS trial, which was conducted in patients with newonset type 2 diabetes, and which used regular in-trial graded photography for retinal assessment, the risk of two-step progression of DR during the first 3 years was 15.8% with intensive therapy vs 15.3%
with conventional therapy in newly diagnosed patients with type 2 diabetes who were undergoing treatment with either insulin or a sulphonylurea, and by 9 years there was a sustained significant protective effect of improved control. 10 The long-term risk reduction of DR progression was significantly better in intensively (23.0%) vs conventionally (27.8%) treated patients after 6 years of follow-up (P = 0.017).
10
Early worsening was also demonstrated in a retrospective casecontrol study in 68 public hospital patients with type 2 diabetes, predominantly from ethnic minorities (Latino/other). These patients underwent annual retinal imaging either as part of a case management programme or as standard diabetes care. 33 An "intensive"
group of patients (n = 34) with an HbA1c decrease of more than 1.5% was compared with randomly chosen (control) patients (n = 34) with minimal HbA1c changes over 2 years. In this study, the inten- vs eyes in the control group. 33 This study supports DCCT findings that DR is significantly worsened in poorly controlled type 2 diabetes after early intensification of glycaemic control and a dramatic change in HbA1c. 17, 33 As is the case for patients with type 1 diabetes, there is a large body of evidence supporting a beneficial effect of tight glycaemic control in the long term for patients with type 2 diabetes. The ACCORD eye study, for example, demonstrated reduced incidence or progression of DR. This study investigated whether intensive glycaemic control, combination therapy for dyslipidaemia and intensive BP control could limit DR in patients with type 2 diabetes. 25 Participants (N = 10 251) were randomly assigned to receive either intensive (tar- Post hoc analysis of VADT prospective study
• Poorly controlled type 2 diabetes completing 7-field stereo fundus photos at baseline and 5 y • N = 858
• Odds of DR progression lower by $40% in those with baseline TC ≥200 mg/dL (P = 0.007), LDL-C ≥120 mg/dL (P < 0.02) or HDL-C ≥40 mg/ dL (P < 0.007) in INT versus standard glycaemic treatment • Odds of DR progression lower by $40-50% with reductions of TC by ≥40 mg/dL (p < 0.0001), of LDL-C of ≥40 mg/dL (P < 0.004), and of TG by ≥60 mg/dL (P = 0.004) at year 5 • INT associated with decreased odds of progression but not with onset of retinopathy in those with worse lipid levels at baseline and more improved lipid levels during the study insulin group, respectively, experienced DR progression. 36, 37 Subsequently, an in vitro study showed insulin glargine to have greater binding affinity for the insulin-like growth factor 1 (IGF-1) receptor compared with NPH insulin. 38 It was hypothesized that this might lead to the increased risk of DR progression with insulin glargine. However, this was disputed by the results of a 5-year trial investigating DR with insulin glargine vs NPH, which showed no difference in the rate of DR progression. 37 Subsequently, the ORIGIN study found that there was no significant difference between the insulin glargine group and the standard-of-care group in the occurrence of microvascular events. 39 
| EARLY WORSENING WITH NON-INSULIN THERAPIES
The evidence for early worsening of DR with non-insulin therapies continues to grow. Glucagon-like peptide-one receptor agonists (GLP1RAs), such as exenatide, liraglutide and semaglutide, exemplify a non-insulin-therapy drug class that is associated with increased rates of DR complication events, including early worsening of DR. 11, 26, [40] [41] [42] However, not all increases were significant when compared with placebo. 41 In a retrospective cohort study in patients with type 2 diabetes, higher with greater reductions in HbA1c. 43 Follow-up data from this study showed that sustained treatment with exenatide resulted in 80% of patients having an improved (62%) or stable (18%) DR status after a mean 439 days (1.2 years) from the phase 1 screening; initial DR screening took place 234 days (8 months) from baseline. 40 In the LEADER trial, DR complications, defined as the need for retinal photocoagulation or treatment with intravitreal agents, vitreous haemorrhage or the onset of diabetes-related blindness, was evaluated in patients with type 2 diabetes and high cardiovascular risk. In this study the incidence of DR complications was non-significantly higher in patients receiving liraglutide compared to those receiving placebo (0.6 vs 0.5 events per 100 patient-years; HR, 1.15; 95% CI, 0.87-1.52; P = 0.33). 41 Similarly, semaglutide was associated with an increased rate of DR complications in the SUSTAIN 6 study, a pre-approval trial to evaluate cardiovascular and other long-term outcomes in patients with type 2 diabetes. 11 DR complications were significantly higher in the SUSTAIN 6 trial with semaglutide vs placebo (HR, 1.76; 95% CI, 1.11-2.78; P = 0.02).
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It is important to emphasize that both the LEADER and the SUS- A subsequent SUSTAIN 6 post hoc analysis suggests that the increased risk of DR with semaglutide may not be an agent-specific effect, but rather, attributable to the rapidity and magnitude of HbA1c reduction during the first 16 weeks of treatment in patients with preexisting DR and poor glycaemic control at baseline who were undergoing treatment with insulin (Table 2) . 26 Furthermore, it has been hypothesized that the worsening of DR in the SUSTAIN 6 trial may be accounted for, in part, by the inclusion of patients with advanced nonproliferative or proliferative DR, in whom semaglutide may have triggered neovascularization. However, there is no information available from either in vitro or in vivo studies on the angiogenic effect of GLP-1RA in the retina, and further investigation is required. 42 Across the rest of the SUSTAIN Phase 3a clinical development programme (SUSTAIN 1 to 5 and Japan-based trials) and in SUSTAIN 7, in which patients with sight-threatening DR were excluded, there was no increase in DR adverse events in patients treated with semaglutide vs comparators. 26, 44 Furthermore, an assessment using the Food and Drug Administration Adverse Event Reporting System has shown no evidence that GLP-1RAs are associated with adverse events suggestive of DR progression. 45 A meta-analysis assessing the effects of GLP-1RAs on DR showed that treatment with GLP-1RAs was not associated with a significant increase in the incidence of retinopathy (Mantel-Haenszel odds ratio, 0.92; 95% CI, 0.74-1.16; P = 0.49). However, this analysis did not evaluate early worsening of DR. 46 In experimental animal models of early-stage DR, systemically and locally administered GLP-1RAs prevented neurodegeneration of the retina and protected from diabetes-related changes to the retina. [47] [48] [49] Similarly, DPP4 inhibitors had a protective effect on retinal microvasculature and prevented neurodegeneration and vascular leakage in the diabetic retina. 50, 51 This evidence for a direct beneficial effect of GLP-1RAs on the retina supports the hypothesis that early worsening of DR in the SUSTAIN 6 trial may be attributed to rapid improvement in glucose control in insulin-treated patients with pre-existing retinopathy, rather than to direct retinal toxicity of GLP-1RAs.
45,47-49

| EARLY WORSENING FOLLOWING BARIATRIC SURGERY
The effect of bariatric surgery on DR and early worsening remains debatable. Existing data support positive, neutral and negative effects of bariatric surgery on DR. 52 The potential risk factors for DR progression following bariatric surgery may include pre-operation DR severity, magnitude of post-surgery HbA1c reduction and, in some cases, gender and ethnicity. 53, 54 Uncontrolled studies suggest that bariatric surgery may contribute to the worsening of pre-existing DR following surgery. 53, 55 A meta-analysis of four non-randomized case studies (N = 148)
showed that, in patients with DR prior to surgery (n = 68), 57.4% AE 18.5% of patients experienced no change, 23.5% AE 18.7% experienced progression and 19.2% AE 2.9% experienced an improvement in DR. In patients without pre-operative DR (n = 80) an average of 92.5% AE 7.4% remained DR free, while 7.5% AE 7.4%
progressed to DR. The odds ratio for DR progression in patients with pre-operative DR compared to those without was 2.77 (95% CI, 1.10 to 6.9; P = 0.03). 55 However, data concerning the time points after bariatric surgery when no change occurred or when progression or improvements in DR occurred, or how the improved DR rate was assessed, are important considerations when interpreting findings. In a retrospective observational study of patients with type 2 diabetes (N = 102) to assess whether bariatric surgery prevented DR progression, the overall incidence of new retinopathy was 24%. In this study, young male patients with pre-existing DR and poor pre-operative glycaemic control, who did not have significantly improved post-operative HbA1c levels, were at most risk of DR progression. 53 A pilot study in patients with type 2 diabetes and morbid obesity showed that moderate background DR, or worse, increased the risk of DR progression, while minimal DR or the absence of DR resulted in a low incidence of new-onset DR and DR progression. 56 Findings from a retrospective, observational study in patients with type 2 diabetes showed that the probability of DR progression, to moderate or higher severity, after bariatric surgery was associated with the magnitude of HbA1c reduction from pre-surgery levels, with a short duration of post-operative retinal screening, with severe pre-operative DR, with male gender and with ethnicity. 54 In other studies, bariatric surgery has been shown to have no effect on DR deterioration. For example, a survey of the Scandinavian Obesity Surgery Registry showed that, in 117 patients with type 2 diabetes, the majority of patients experienced no post-surgery DR deterioration (mean, 16 months after surgery; unspecified method of evaluating DR). Furthermore, no association between pre-operative body mass index (BMI), HbA1c or reduction in HbA1c and worsening of DR progression was reported. 57 Conversely, some studies have shown an improvement in DR progression following bariatric surgery. For example, a meta-analysis of seven controlled studies indicated that bariatric surgery prevented new incident cases of retinopathy. However, there were insufficient data to support reduced progression or regression of DR. 58 Similarly, in a retrospective observational cohort study (N = 4683; 40% racial/ ethnic minority, Hispanic, non-Hispanic black or other), patients who experienced remission of type 2 diabetes after bariatric surgery had a 29% lower risk of microvascular complications, including first occurrence of retinopathy. Furthermore, in patients who eventually relapsed, for every year they remained in remission, they experienced a 19% risk reduction in microvascular disease compared to patients who did not go into remission. 59 
| EARLY WORSENING DURING PREGNANCY
Pregnancy is a risk factor for DR progression and is associated with increased DR prevalence and severity compared to that in nonpregnant women with diabetes. The highest risk of DR worsening occurs in the second trimester and can persist for up to 12 months post-partum. Factors associated with DR progression during pregnancy include diabetes duration, DR severity at conception, hyperglycaemic control, anaemia and coexisting hypertension. 60 These risk factors have been confirmed in a Japan-based study (N = 93; type 1 diabetes, n = 68 and type 2 diabetes, n = 25) in which progression of DR occurred in 17% of patients. In this study, patients who experienced DR progression had a significantly longer duration of diabetes (P < 0.00001), had pre-pregnancy DR (P < 0.00001) and had higher BP in the second trimester (P < 0.05) compared to patients who did not experience DR progression. 61 Rapid implementation of tight glycaemic control has also been associated with worsening of retinopathy in pregnant women with type 1 diabetes. 62 Guidelines recommend that pregnant women with pre-existing diabetes be offered retinal assessment by examination and fundus retinal imaging. In addition, guidelines suggest that DR
should not be considered a contraindication to rapid glycaemic control in women with high HbA1c in early pregnancy, but rather, that retinal assessment is essential in such individuals. 63 
| THEORIES CONCERNING THE PARADOXICAL EARLY WORSENING OF DR
Several theories exist to explain the paradoxical worsening of DR that is evident in patients with diabetes following rapid and large reductions in blood glucose. However, as there are currently no suitable animal models of DR, there are significant limitations associated with such theories.
| Osmotic force theory
Glucose is an osmotically active molecule and can influence water movements. Thus, changes in blood glucose concentrations can alter osmotic pressure, which in turn affects water retention. Earlier, we described how rapid reductions in blood glucose affect osmotic pressure and the extracellular and intravascular areas. and the number of days required for the development and resolution of hyperopic changes (P < 0.0001). 64 This correlation alone, however, is insufficient evidence for causation.
| Synergistic hypothesis
The synergistic hypothesis postulates that early worsening is caused by the synergistic action of insulin and VEGF on blood vessels in the retina, triggering vascular proliferation and, therefore, worsening DR. 27 In an in vitro study, insulin was found to increase reactive oxygen species (ROS) in bovine retinal endothelial cells. This increased insulin-induced ROS production and VEGF expression, in the presence of high glucose, may explain early worsening DR (Table 3) . 65 
| Blood-retinal barrier
Another mechanism that has been suggested to explain transient worsening of DR is that involving a breakdown of the blood-brain barrier following intensive insulin therapy. An in vitro study demonstrated an increase in VEGF mRNA and protein levels in the retinas of diabetic rats following acute intensive insulin therapy. Retinal nuclear The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells
Human and bovine retinal cells
• Lack of both oxygen and glucose led to significant upregulation of VEGF production, whereas lack of oxygen but excess glucose led to downregulation of VEGF • Sufficient oxygen with excess glucose had no effect on VEGF production • "Early worsening" of DR may result when diabetic patients with minimal to moderate retinopathy, whose retinal circulation and, hence, retinal oxygen supply is compromised, are placed on a "tight" glucose control regimen and their major remaining retinal energy source is reduced, with VEGF upregulation as a compensatory mechanism extracts from insulin-treated rats had high levels of hypoxia-inducible factor-1α (HIF-1α). Thus, acute intensive insulin therapy led to bloodretinal barrier breakdown via an HIF-1α-mediated increase in retinal VEGF expression, resulting in transient DR (Table 3) . 66 
| VEGF hypothesis
Tight glycaemic control in an hypoxic environment may lead to VEGF upregulation. In a series of in vitro experiments in human and bovine retinal cells, the lack of both oxygen and glucose led to significant upregulation of VEGF production, whereas lack of oxygen in combination with excess glucose led to downregulation of VEGF and sufficient oxygen with excess glucose had no effect on VEGF production. 67 In rat cells, transient ischaemia, followed by retinal reperfusion, led to a significant increase in VEGF. VEGF expression was linked to vascular permeability. 68 In addition, a study of 26 patients newly diagnosed with type 1 or type 2 diabetes showed that, in those who experienced blurred vision after initiating insulin therapy, a transient increase in macular volume and thickness followed, which is associated with a decrease in the circulating soluble VEGF receptor, sFlt-1 (Table 3 ). Blocking fatty acid oxidation led to reduced ROS production, inhibiting disease progression and suggesting that hypoglycaemia-induced mtROS production may contribute to early worsening of DR (Table 3) . 70 In another study using human retinal epithelial cells, the rapid achievement of good glycaemic control did not trigger an immediate effect on the retinal DNA methylation-hydroxymethylation machinery associated with DR progression. In this study, good glycaemic control for a longer duration, and/or direct targeting of DNA methylation, improved mitochondrial damage and could therefore potentially slow DR progression (Table 3) . 71 The relationship between hypoglycaemia and ischaemic retinopathy was investigated in an in vivo study using Wistar rats. In this study, reduced blood glucose levels or hypoglycaemia caused a significant (P < 0.001) reduction in vitreous glucose concentration, thereby exacerbating ischaemic retinal injury (Table 3) . 72 The role of epigenetic modifications in early worsening of DR following tight glycaemic control remains to be fully investigated.
| CONCLUSIONS
Early worsening of DR is a well-described phenomenon evident in patients with type 1 and type 2 diabetes, in those who have undergone bariatric surgery and in pregnant women. 13 It does not appear to be agent-specific as it has been described in patients receiving diverse treatments, including intensive insulin therapy, sulphonylureas, thiazolidinediones and GLP-1RAs. [4] [5] [6] 10, 11, 26, 40, 41 Morphological retinal changes that occur in early worsening include cotton-wool spots/soft exudates, IRMAs, retinal haemorrhages and progression to severe non-proliferative or proliferative forms of DR. 3, 6, 9, 16, 17 While the mechanism leading to early worsening remains unclear, most evidence suggests an association with glycaemic control. The most important factors that are linked with early worsening of DR following rapid improvement of hyperglycaemia are a large reduction in HbA1c (<2%) and the severity of pre-existing DR at baseline. 17, 30, 33 Consequently, insulin labels carry a warning of the risk of early worsening of DR with large and rapid reductions in HbA1c in patients with diabetes. 73 Although a gradual improvement in HbA1c is possible with insulin, this may not be possible with treatments such as GLP-1RAs, where the improvement in glycaemic control can be rapid and profound. Poorly controlled hypertension is another potential risk factor associated with early worsening. Eye status should be assessed in patients at increased ocular risk prior to initiating intensive treatments to achieve glycaemic control, and patients should be informed of the risk and reassured that both the transient loss of visual acuity and the possible change in retinal architecture are small risks compared with the proven long-term benefits of glycaemic control.
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